Table 1.
Baseline characteristics of follicular lymphoma patients with early therapy failure.
| Variable | No AutoHCT- cohort (NLCS) (%) | AutoHCT- Cohort (CIBMTR) (%) | p-value |
|---|---|---|---|
| Number of patients | 174 | 175 | |
| Median age at diagnosis, years (range) | 55 (31–69) | 53 (22–69) | <0.0001 |
| 18–39 | 12 (7) | 23 (13) | |
| 40–49 | 33 (19) | 47 (27) | |
| 50–59 | 66 (38) | 57 (33) | |
| 60–64 | 31 (18) | 31 (18) | |
| 65–70 | 32 (18) | 17 (10) | |
| Median Age at autoHCT, years (range) | N/A | 55 (23–75) | N/A |
| ≥65 | 30 (17) | ||
| Male sex | 100 (57) | 105 (60) | 0.63 |
| KPS at diagnosis | |||
| 90–100% | 58 (33) | Not available | N/A |
| <90% | 52 (30) | ||
| Missing | 64 (37) | ||
| Karnofsky Score at autoHCT | |||
| 90–100% | N/A | 114 (65) | |
| <90% | 46 (26) | ||
| Missing | 15 (9) | ||
| Race | 0.008 | ||
| Caucasian | 149 (86) | 162 (93) | |
| African-American | 12 (7) | 5 (3) | |
| Other1 | 13 (7) | 3 (1) | |
| Unknown | 0 | 5 (3) | |
| Advanced stage (III/IV) at diagnosis | 155 (89) | 140 (80) | 0.06 |
| Missing | 0 | 4 (2) | |
| WHO Grade | 0.04 | ||
| 1/2 | 117 (67) | 104 (59) | |
| 3 | 40 (23) | 62 (35) | |
| Unknown | 17 (10) | 9 (5) | |
| Median time from diagnosis to HCT, months (range) | N/A | 23 (6–86) | |
| Median time from treatment failure to HCT, months (range) | N/A | 6 (2–82) | |
| <1 year | 123 (70) | ||
| ≥1 year | 52 (30) | ||
| Bone marrow positive at diagnosis | 86 (49) | 75 (43) | 0.11 |
| Missing | 15 (8) | 9 (5) | |
| Extranodal sites involved at diagnosis | 120 (69) | 117 (67) | 0.78 |
| Missing | 7 (4) | 9 (5) | |
| Normal LDH at diagnosis | 80 (46) | 34 (19) | 0.02 |
| Unknown | 51 (29) | 104 (59) | |
| FLIPI Score at diagnosis | |||
| Good (0–1) | 24 (14) | Not available | |
| Intermediate (2) | 48 (28) | ||
| Poor (3–5) | 65 (37) | ||
| Unknown | 37 (21) | ||
| Front-line therapy | <0.0001 | ||
| R-CHOP | 100 (57) | 139 (79) | |
| R-CVP | 36 (21) | 20 (11) | |
| R-Fludarabine-containing | 32 (18) | 6 (3) | |
| R-Other2 | 6 (3) | 10 (6) | |
| Response to front-line therapy | 0.004 | ||
| CR/PR | 116 (67) | 136 (78) | |
| Progressive disease | 15 (9) | 5 (3) | |
| Stable disease | 38 (21) | 22 (13) | |
| Unknown | 5 (3) | 12 (7) | |
| Median lines of therapy prior to HCT (range) | N/A | 2 (1–6) | |
| Remission status before HCT | |||
| Complete remission | N/A | 70 (40) | |
| Partial remission | 68 (39) | ||
| Chemorefractory | 30 (17) | ||
| Untreated | 2 (1) | ||
| Missing | 5 (3) | ||
| Conditioning Regimen | |||
| TBI-based | N/A | 23 (13) | |
| BEAM and similar | 119 (68) | ||
| CBV or similar | 27 (15) | ||
| BuMEL/BuCy | 5 (3) | ||
| Carboplatin/Methotrexate/Thiotepa | 1 (<1) | ||
| Year of transplant | |||
| 2002–2003 | N/A | 2 (1) | |
| 2004–2005 | 33 (19) | ||
| 2006–2007 | 65 (37) | ||
| 2008–2009 | 70 (40) | ||
| 2010–2011 | 4 (2) | ||
| 2012 | 1 (<1) | ||
| Median follow-up of survivors (range), months-from 4 months after failure | 76 (2–130) | 71 (6–131) | |
Abbreviations: AutoHCT=autologous hematopoietic cell transplantation; BEAM=carmustine, etoposide, cytarabine, melphalan; BuCy=busulfan, cyclophosphamide; BuMel=busulfan, melpahlan; CBV=cyclophosphamide, carmustine; etoposide; CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone; CIBMTR: Center for International Blood and Marrow Transplant Research; CVP= cyclophosphamide, vincristine, prednisone; FLIPI=follicular lymphoma international prognostic index; KPS=Karnofsky Performance Score; LDH=lactate dehydrogenase; NLCS=National LymphoCare Study; R=rituximab; TBI=total body irradiation.
CIBMTR cohort: Asian (n=1), Native American (n=2); NLCS cohort: Not otherwise specified=13
CIBMTR cohort: Carboplatin/R-CHOP (n=1), R/carboplatin/VP16/ifosphamide (n=1), R-steroids/cyclophosphamide/ara-C/vincristine (n=1), R-ara-c/doxorubicin/cyclophosphamide (n=1), R-cyclophosphamide/pentostatin (n=1), R-cyclophosphamide/vincristine (n=2), R-doxorubicin/vincristine (n=1), R-doxorubicin/bleomycin/dacarbazine/vinblastine (n=1), R-taxol (n=1). NLCS cohort: R/carboplatin/VP16/ifosphamide (n=1), R-cyclophosphamide/ara-c/doxorubin/VP16/steroid/vincristine/methotrexate/bleomycin (n=1), R-cyclophosphamide/vincristine (n=2), R-cisplatin/cyclophosphamide/ara-c/doxorubicin/VP16/methotrexate/steroids/vincristine (n=1), R-bortezomib/leukine (n=1)